Obesity: a modern view on the problem

DOI: https://doi.org/10.29296/25877305-2020-03-01
Download full text PDF
Issue: 
3
Year: 
2020

Professor K. Amlaev, MD; L. Blinkova, Candidate of Medical Sciences; Kh. Dakhkilgova Stavropol State Medical University

Obesity is one of the most important problems of current health care; the number of obese people is increasing annually. The authors present the epidemiology, etiology, pathogenesis of this disease; special attention is paid to the hormonal functions of adipose tissue and to adipokines produced by the latter. Modifiable and non-modifiable risk factors for this disease are considered separately. The paper highlights an association between obesity and comorbidities (circulatory system diseases, cancer, diabetes mellitus, non-alcoholic fatty liver disease, sleep apnea syndrome, and infertility). It describes the impact of the gut microflora on the development of this disease. Obesity-diagnosing methods and nondrug and drug therapies in patients with obesity are considered.

Keywords: 
endocrinology
obesity
lifestyle
adipose tissue
oxidative stress
comorbidity
physical inactivity



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. GHO. Prevalence of overweight among adults, BMI ≥25, age-standardized – Estimates by country. [online] Available at: http://apps.who.int/gho/data/node.main.A897A?lang=en [Accessed 12 Oct. 2019].
  2. Amlaev K.R., Bzhezovskaja M.M. Rezul'taty sotsiologicheskogo issledovanija obraza zhizni molodezhi Stavropolja // Profilakticheskaja meditsina. – 2010; 1: 17–21 [Amlaev K.R., Bzhezovskaya M.M. Results of sociological survey of lifestyle in the youth of Stavropol // Profilakticheskaja medicina. – 2010; 1: 17–21 (in Russ.)].
  3. Bray G., Frühbeck G., Ryan D. et al. Management of obesity // Lancet. – 2016; 387 (10031): 1947–56. DOI: 10.1016/s0140-6736(16)00271-3.
  4. Haczeyni F., Bell-Anderson K., Farrell G. Causes and mechanisms of adipocyte enlargement and adipose expansion // Obesity Rev. – 2017; 19 (3): 406–20. DOI: 10.1111/obr.12646.
  5. Jordan B., Gourgue F., Cani P. Adipose Tissue Metabolism and Cancer Progression: Novel Insights from Gut Microbiota? // Curr. Pathobiol. Rep. – 2017; 5 (4): 315–22. DOI: 10.1007/s40139-017-0154-6.
  6. Luong Q., Huang J., Lee K. Deciphering White Adipose Tissue Heterogeneity // Biology. – 2019; 8 (2): 23. DOI: 10.3390/biology8020023.
  7. Akbari M., Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes // Inflammopharmacology. – 2018; 26 (3): 685–98. DOI: 10.1007/s10787-018-0458-0.
  8. Xu E., Pereira M., Karakasilioti I. et al. Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance // Nature Communications. – 2017; 8 (1): 14803. DOI: 10.1038/ncomms14803
  9. Choe S., Huh J., Hwang I. et al. Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders // Front. Endocrinol. – 2016; 7: 30. DOI: 10.3389/fendo.2016.00030.
  10. Sramkova V., Berend S., Siklova M. et al. Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction // Am. J. Clin. Nutr. – 2019; 109 (6): 1499–510. DOI: 10.1093/ajcn/nqy331.
  11. Smith U., Kahn B. Adipose tissue regulates insulin sensitivity: role of adipogenesis,de novolipogenesis and novel lipids // J. Int. Med. – 2016; 280 (5): 465–75. DOI:10.1111/joim.12540.
  12. Hafidi M., Buelna-Chontal M., Sánchez-Muñoz F. et al. Adipogenesis: A Necessary but Harmful Strategy // Int. J. Mol. Sci. – 2019; 20 (15): 3657. DOI: 10.3390/ijms20153657.
  13. Cohen P., Spiegelman B. Brown and Beige Fat: Molecular Parts of a Thermogenic Machine // Diabetes. – 2015; 64 (7): 2346–51. DOI: 10.2337/db15-0318.
  14. Hilton C., Karpe F., Pinnick K. Role of developmental transcription factors in white, brown and beige adipose tissues // Biochimica et Biophysica Acta (BBA) – Molecular and Cell Biology of Lipids. – 2015; 1851 (5): 686–96. DOI: 10.1016/j.bbalip.2015.02.003.
  15. Stinkens R., Goossens G., Jocken J. et al. Targeting fatty acid metabolism to improve glucose metabolism // Obesity Rev. – 2015; 16 (9): 715–57. DOI: 10.1111/obr.12298.
  16. Goossens G. The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function // Obesity facts. – 2017; 10 (3): 207–15. DOI: 10.1159/000471488.
  17. Karpe F., Pinnick K. Biology of upper-body and lower-body adipose tissue – link to whole-body phenotypes // Nat. Rev. Endocrinol. – 2014; 11 (2): 90–100. DOI:10.1038/nrendo.2014.185.
  18. Blüher M. Are metabolically healthy obese individuals really healthy? // Eur. J. Endocrinol. – 2014; 171 (6): R209–19. DOI: 10.1530/EJE-14-0540.
  19. Bell J., Kivimaki M., Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies // Obesity Rev. – 2014; 15 (6): 504–15. DOI: 10.1111/obr.12157.
  20. Eckel N., Meidtner K., Kalle-Uhlmann T. et al. Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis // Eur. J. Prev. Cardiol. – 2015; 23 (9): 956–66. DOI: 10.1177/2047487315623884.
  21. Appleton S., Seaborn C., Visvanathan R. et al. Diabetes and Cardiovascular Disease Outcomes in the Metabolically Healthy Obese Phenotype: A cohort study // Diabetes Care. – 2013; 36 (8): 2388–94. DOI: 10.2337/dc12-1971.
  22. Grover S., Kaouache M., Rempel P. et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study // Lancet. Diabetes & Endocrinology. – 2015; 3 (2): 114–22. DOI: 10.1016/s2213-8587(14)70229-3.
  23. Bourdier L., Orri M., Carre A. et al. Are emotionally driven and addictive-like eating behaviors the missing links between psychological distress and greater body weight? // Appetite. – 2018; 120: 536–46. DOI: 10.1016/j.appet.2017.10.013.
  24. Meldrum D., Morris M., Gambone J. Obesity pandemic: causes, consequences, and solutions – but do we have the will? // Fertility and Sterility. – 2017; 107 (4): 833–9. DOI: 10.1016/j.fertnstert.2017.02.104.
  25. Boulangé C., Neves A., Chilloux J. et al. Impact of the gut microbiota on inflammation, obesity, and metabolic disease // Genome Medicine. – 2016; 8 (1): 42. DOI: 10.1186/s13073-016-0303-2.
  26. Rosenquist K., Massaro J., Pedley A. et al. Fat Quality and Incident Cardiovascular Disease, All-Cause Mortality, and Cancer Mortality // J. Clin. Endocrinol. Metab. – 2015; 100 (1): 227–34. DOI: 10.1210/jc.2013-4296.
  27. Abraham T., Pedley A., Massaro J. et al. Association Between Visceral and Subcutaneous Adipose Depots and Incident Cardiovascular Disease Risk Factors // Circulation. – 2015; 132 (17): 1639–47. DOI: 10.1161/circulationaha.114.015000.
  28. Nakamura K., Fuster J., Walsh K. Adipokines: A link between obesity and cardiovascular disease // J. Cardiol. – 2014; 63 (4): 250–9. DOI: 10.1016/j.jjcc.2013.11.006.
  29. 29. Matsuo K., Shibata R., Ohashi K. et al. Omentin functions to attenuate cardiac hypertrophic response // J. Mol. Cell. Cardiol. – 2015; 79: 195–202. DOI: 10.1016/j.yjmcc.2014.11.019.
  30. Fuster J., Ouchi N., Gokce N. et al. Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease // Circulation Research. – 2016; 118 (11): 1786–807. DOI: 10.1161/circresaha.115.306885.
  31. Manna P., Jain S. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies // Metab. Syndr. Relat. Disord. – 2015; 13 (10): 423–44. DOI: 10.1089/met.2015.0095.
  32. Aune D., Sen A., Prasad M. et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants // BMJ. – 2016; 353: i2156. DOI: 10.1136/bmj.i2156.
  33. Di Angelantonio E., Bhupathiraju S., Wormser D. et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents // Lancet. – 2016; 388 (10046): 776–86. DOI: 10.1016/s0140-6736(16)30175.
  34. Wang J., Jia Y., Wang L. et al. Vasodilator-Stimulated Phosphoprotein: Regulators of Adipokines Resistin and Phenotype Conversion of Epicardial Adipocytes // Med. Sci. Monit. – 2018; 24: 6010–20. DOI: 10.12659/MSM.908111.
  35. Milić S., Lulić D., Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations // World J. Gastroenterol. – 2014; 20 (28): 9330–7. DOI: 10.3748/wjg.v20.i28.9330.
  36. Marchi J., Berg M., Dencker A. et al. Risks associated with obesity in pregnancy, for the mother and baby: a systematic review of reviews // Obesity Rev. – 2015; 16 (8): 621–38. DOI: 10.1111/obr.12288.
  37. Boeing H., Bechthold A., Bub A. et al. Critical review: vegetables and fruit in the prevention of chronic diseases // Eur. J. Nutr. – 2012; 51 (6): 637–63. DOI: 10.1007/s00394-012-0380-y.
  38. Tchernof A., Després J.-P. Pathophysiology of human visceral obesity: an update // Physiol. Rev. – 2013; 93 (1): 359–404. DOI: 10.1152/physrev.00033.2011.
  39. Martin C., Redman L., Zhang J. et al. Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure // J. Clin. Endocrinol. Metab. – 2011; 96 (3): 837–45. DOI: 10.1210/jc.2010-1848.
  40. Kang Y., Cai Y. The development of probiotics therapy to obesity: a therapy that has gained considerable momentum // Hormones. – 2018; 17 (2): 141–51. DOI: 10.1007/s42000-018-0003-y.